Secondary cytoreduction versus chemotherapy alone in the treatment of patients with recurrent ovarian cancer: is a randomized trial worthwhile?
Curr Oncol Rep
.
2013 Jun;15(3):191.
doi: 10.1007/s11912-013-0302-z.
Authors
Paolo Sammartino
,
Daniele Biacchi
,
Marialuisa Framarino
PMID:
23443489
DOI:
10.1007/s11912-013-0302-z
No abstract available
Publication types
Letter
Kommentar
MeSH terms
Female
Humans
Neoplasm Recurrence, Local / surgery*
Ovarian Neoplasms / surgery*
Ovary*